Substance / Medication

Bimatoprost

Overview

Active Ingredient
bimatoprost
RxNorm CUI
283810

Indications

ZOLYMBUS™ is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Labeler: Thea Pharma Inc.Updated: 2026-02-25T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Adverse Reactions (6.2) [see] ZOLYMBUS is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.
Fang Yuan, Ling Zhihong, Sun Xinghuai · Drug Des Devel Ther · 2015
PMID: 25999695Meta-AnalysisFull text (PMC)
The Efficacy of 308-nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo.
Ghiasi Maryam, Isazade Ahdie, Marhamati Tahereh et al. · J Cosmet Dermatol · 2025
PMID: 39968721RCTFull text (PMC)
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
Kolko Miriam, Tatham Andrew J, Lim Kin Sheng et al. · Am J Ophthalmol · 2025
PMID: 39800203RCT
Enhancing hair regrowth in Alopecia areata: the power duo of CO2 fractional laser and Bimatoprost.
Nouh Ahmed Hassan, Behairy Ayaat Abd Elghany, El-Koumy Fatma Badr et al. · Arch Dermatol Res · 2025
PMID: 40252129RCT
MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans Ingeborg, Lim Kin Sheng, Oddone Francesco et al. · Graefes Arch Clin Exp Ophthalmol · 2024
PMID: 37615697RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bimatoprost (substance)
SNOMED CT
129492005
UMLS CUI
C0937917
RxNorm CUI
283810
Labeler
Thea Pharma Inc.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.